OncoMatch/Clinical Trials/NCT07324824
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
Is NCT07324824 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies sintilimab combined with bevacizumab biosimilar for hepatocellular carcinoma.
Treatment: sintilimab combined with bevacizumab biosimilar — Surgical resection is the preferred therapeutic modality for patients with resectable hepatocellular carcinoma (HCC). However, the recurrence rate of HCC remains up to 70%. Neoadjuvant therapy for HCC could potentially reduce the risk of postoperative recurrence and prolong overall survival. Nevertheless, there is no standard neoadjuvant treatment regimen for HCC to date. In recent years, targeted therapy and immunotherapy are proved to improve the prognosis of advanced HCC patients. Previous study (ORIENT-32) has confirmed that, compared with sorafenib, sintilimab combined with bevacizumab biosimilar can delay tumor progression, reduce the risk of death, and exhibit a favorable safety profile in patients with advanced HCC. Therefore, we conducted a prospective, single-arm phase II study to investigate the efficacy of sintilimab combined with a bevacizumab biosimilar as neoadjuvant therapy in patients with resectable HCC beyond the Milan criteria.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage IB, IIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-angiogenic agent
Prior receipt of any anti-angiogenic agents
Cannot have received: anti-PD-1 therapy
Prior receipt of any ... anti-PD-1 antibodies
Cannot have received: anti-PD-L1 therapy
Prior receipt of any ... anti-PD-L1/L2 antibodies
Cannot have received: anti-PD-L2 therapy
Prior receipt of any ... anti-PD-L1/L2 antibodies
Cannot have received: anti-CTLA-4 therapy
Prior receipt of any ... anti-CTLA-4 antibodies
Cannot have received: immunotherapy
Prior receipt of any ... other immunotherapies
Lab requirements
Blood counts
sufficient organ and bone marrow function
Liver function
child-pugh class a
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify